tedizolid phosphate (sivextro) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Tedizolid phosphate is an oxazolidinone prodrug which in the body is dephosphorylated to the active compound tedizolid. The antibacterial activity of tedizolid is mediated by binding to the 50S subunit of the bacterial ribosome resulting in inhibition of protein synthesis. Tedizolid inhibits bacterial protein synthesis through a mechanism of action different from that of other non-oxazolidinone class antibacterial drugs; therefore, cross-resistance between tedizolid and other classes of antibacterial drugs is unlikely. Tedizolid is bacteriostatic against Gram Positive bacteria such as enterococci, staphylococci, and streptococci. No drug-drug interactions were identified with tedizolid.   NCATS

Chemistry

  • SMILES: CN1N=NC(=N1)C2=NC=C(C=C2)C3=CC=C(C=C3F)N4C[C@H](CO)OC4=O
  • InChIKey: XFALPSLJIHVRKE-GFCCVEGCSA-N
  • Mol. Mass: 370.3378
  • ALogP: 1.4
  • ChEMBL Molecules:
    tedizolid  
    tedizolid phosphate  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$277.8227 - $2294.2200
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

3-(3-fluoro-4-(6-(2-methyl-2h-tetrazol-5-yl)pyridin-3-yl)phenyl)-5-(hydroxymethyl)oxazolidin-2-one | 3-(3-fluoro-4-(6-(2-methyl-2h-tetrazol-5-yl)pyridin-3-yl)phenyl)-5-hydroxymethyloxazolidin-2-one | [(5r)-3-{3-fluoro-4-[6-(2-methyl-2h-tetrazol-5-yl)pyridin-3-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl]methyl dihydrogen phosphate | da7218 | da 7218 | da-7218 | sivextro | tedizolid | tedizolid phosphate | torezolid | torezolid phosphate | tr 700 | tr-700 | tr 701 | tr-701 | tr701 cpd | tr-701-fa

Organizations (15)

Research & Development (15)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (14)

Approved Indications (3)


 

Skin Diseases, Bacterial (approved 2014)

Skin Diseases, Infectious (approved 2014)

Staphylococcal Skin Infections (approved 2014)

Experimental Indications - Clinical Trial Phases 1-4 (13)


 

Bacterial Infections (Phase 3)

Bone Diseases, Infectious (Phase 2)

Cystic Fibrosis (Phase 4)

Diabetes Mellitus (Phase 1)

Gram-Positive Bacteria (Phase 1)

Gram-Positive Bacterial Infections (Phase 1)

Healthy Volunteers (Phase 1)

Obesity (Phase 4)

Pneumonia (Phase 3)

Prosthesis-Related Infections (Phase 4)

Skin Diseases, Bacterial (Phase 3)

Skin Diseases, Infectious (Phase 3)

Wound Infection (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 19
  • # of Trial Organizations: 15

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue